News
08-18-2011, 10:10 AM
The Mayo Clinic is excited to announce a Phase I study of a new therapeutic vaccine in HER-2/neu positive breast cancer patients in the fourth quarter of 2011. To understand the importance of this development, the HER-2/neu and the significance of HER-2/neu positive breast cancer must be examined...
More... (http://www.medicalnewstoday.com/articles/232991.php)
More... (http://www.medicalnewstoday.com/articles/232991.php)